Gene · 554
Papers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 2,697
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Rare Case of Coexisting Psychogenic Polydipsia and Nephrogenic Diabetes Insipidus With Lithium Therapy. | Cureus | 2022 | 35481319 | PubTator, text mining | PubMed |
| Salt Tablets Safely Increase Serum Sodium in Hospitalised Elderly Patients With Hyponatraemia Secondary to Refractory Idiopathic Syndrome of Inappropriate Anti-Diuresis. | Cureus | 2022 | 35475246 | PubTator, text mining | PubMed |
| Rates of In-Hospital Decongestion and Association with Mortality and Cardiovascular Outcomes Among Patients Admitted for Acute Heart Failure. | Am J Med | 2022 | 35472391 | PubTator, text mining | PubMed |
| Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity. | Pituitary | 2022 | 35451730 | PubTator, text mining | PubMed |
| Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial. | Trials | 2022 | 35449020 | PubTator, text mining | PubMed |
| Remarkable diversity of vomeronasal type 2 receptor (OlfC) genes of basal ray-finned fish and its evolutionary trajectory in jawed vertebrates. | Sci Rep | 2022 | 35440756 | PubTator, text mining | PubMed |
| Identification of potential pathogenic genes for severe aplastic anemia by whole-exome sequencing. | J Clin Lab Anal | 2022 | 35435273 | PubTator, text mining | PubMed |
| Oral disintegrating desmopressin tablet is effective for partial congenital nephrogenic diabetes insipidus with AVPR2 mutation: a case report. | Clin Pediatr Endocrinol | 2022 | 35431445 | PubTator, text mining | PubMed |
| Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. | Transl Behav Med | 2022 | 35429393 | PubTator, text mining | PubMed |
| Determining the Effects of Differential Expression of GRKs and β-arrestins on CLR-RAMP Agonist Bias. | Front Physiol | 2022 | 35422711 | PubTator, text mining | PubMed |
| Heat shock protein family D member 1 in boar spermatozoa is strongly related to the litter size of inseminated sows. | J Anim Sci Biotechnol | 2022 | 35422006 | PubTator, text mining | PubMed |
| Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy. | Stem Cell Res Ther | 2022 | 35410439 | PubTator, text mining | PubMed |
| Flavonoids in Treatment of Chronic Kidney Disease. | Molecules | 2022 | 35408760 | PubTator, text mining | PubMed |
| An Overview of the Heterogeneous Causes of Cushing Syndrome Resulting From Primary Macronodular Adrenal Hyperplasia (PMAH). | J Endocr Soc | 2022 | 35402764 | PubTator, text mining | PubMed |
| Emerging Role of Clinical Genetics in CKD. | Kidney Med | 2022 | 35372818 | PubTator, text mining | PubMed |
| Plasma copeptin is increased and associated with smaller kidney volume in young adults born very preterm. | Clin Kidney J | 2022 | 35371457 | PubTator, text mining | PubMed |
| Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome. | Clin Kidney J | 2022 | 35371438 | PubTator, text mining | PubMed |
| Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease. | J Med Chem | 2022 | 35363466 | PubTator, text mining | PubMed |
| Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options. | Kidney Res Clin Pract | 2022 | 35354242 | PubTator, text mining | PubMed |
| Increased Basal Ganglia Modulatory Effective Connectivity Observed in Resting-State fMRI in Individuals With Parkinson's Disease. | Front Aging Neurosci | 2022 | 35350633 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/554/papers?page=29